Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 9/20 | 0.68 |
| ▸ | MAOB | P27338 | 10/20 | 0.59 |
| ▸ | MAOA | P21397 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | CALML3 | P27482 | 1/20 | 0.58 |
| ▸ | SDHA | P31040 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eperezolid SCHEMBL29421647 | 0.87 | MAOB (0.76) | F10MAOBMAOALMNAPTGS1 | |
| Eperezolid SCHEMBL186562 | 0.87 | MAOB (0.76) | F10MAOBMAOALMNAPTGS1 | |
| Eperezolid SCHEMBL1176950 | 0.87 | MAOB (0.76) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL6160239 | 0.86 | F10 (0.72) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL6160243 | 0.86 | F10 (0.72) | F10MAOBMAOALMNAPTGS1 | |
| Eperezolid SCHEMBL5325217 | 0.86 | MAOB (0.75) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL6157003 | 0.85 | F10 (0.71) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL6156993 | 0.85 | F10 (0.71) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL14319697 | 0.85 | F10 (0.71) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL6040334 | 0.85 | F10 (0.70) | F10MAOBMAOALMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247545-A1 | SUBSTITUTED OXAZOLIDINONE DERIVATIVES | RANBAXY LABORATORIES LIMITED (IN) | 2009-10-01 | — | — | US | disclosed |
| US-20090247545-A1 | SUBSTITUTED OXAZOLIDINONE DERIVATIVES | RANBAXY LABORATORIES LIMITED (IN) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247545-A1 | SUBSTITUTED OXAZOLIDINONE DERIVATIVES | OXA1L, MRPL21, ALPL | F10 3268/4885MAOB 553/4885MAOA 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.